[68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients

Status Terminated

Clinical Trial Summary

This will be an open, single-arm, international, multicentre, phase II imaging study to assess the predictive value of [68Ga]Ga PentixaFor PET imaging in primary and isolated secondary central nervous system lymphoma (CNSL) patients scheduled to undergo induction chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05222269
Study type	Interventional
Source	PentixaPharm GmbH
Contact
Status	Terminated
Phase	Phase 2
Start date	October 5, 2022
Completion date	January 25, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05117814` - Zanubrutinib Monotherapy in Relapsed/Refractory Central Nervous System Lymphoma	N/A
Recruiting	`NCT06132737` - [90Y]Y-PTT Endoradiotherapy in CNS Lymphoma Patients	Phase 1/Phase 2
Terminated	`NCT05242146` - GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma	Phase 1
Completed	`NCT01319591` - Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate
Recruiting	`NCT06322342` - Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent	Phase 2
Recruiting	`NCT05351593` - Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma	Phase 1/Phase 2
Not yet recruiting	`NCT05828628` - CLIMB: CNS Lymphoma Imaging and Molecular Biomarkers Study
Completed	`NCT01182415` - High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma	Phase 2
Not yet recruiting	`NCT06343311` - T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)	Phase 1/Phase 2
Recruiting	`NCT04841434` - A Phase I/II Study to Investigate the Use of VORAXAZE™ as Intended Intervention in Patients With CNSL	Phase 1/Phase 2
Completed	`NCT01083342` - High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study	Phase 2
Completed	`NCT05293990` - Usefulness of Gadovist-enhanced FLAIR Imaging	N/A
Completed	`NCT00596154` - Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma	Phase 2
Recruiting	`NCT05926427` - Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement	Phase 2